OncoCyte Corporation – Consensus Indicates Potential 62.3% Upside

Broker Ratings

OncoCyte Corporation with ticker code (OCX) now have 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 11 and 2 with a mean TP of 7.71. With the stocks previous close at 4.75 this is indicating there is a potential upside of 62.3%. The day 50 moving average is 5.2 and the 200 day MA is 2.97. The company has a market capitalisation of $433m. You can visit the company’s website by visiting: http://oncocyte.com

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp